Masoud Khorshidi1, Aliakbar Sayyari2, Beheshteh Olang2,3, Mohammad Reza Alaei4, Sakineh Shab-Bidar5, Mitra Khalili6, Masoud Salehi7, Naheed Aryaeian8. 1. Department of Community Nutrition, School of Public Health, Iran University of Medical Sciences (IUMS), Hemmat Broadway, Tehran, 1449614535, Iran. 2. Pediatric Gastroenterology, Hepatology and Nutrition Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Department of Community Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Department of Pediatric, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. 6. Department of Radiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 7. Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. 8. Department of Community Nutrition, School of Public Health, Iran University of Medical Sciences (IUMS), Hemmat Broadway, Tehran, 1449614535, Iran. aryaeian.n@iums.ac.ir.
Abstract
BACKGROUND: Type 1 diabetes is a main health burden with several related comorbidities. It has been shown that endothelial function, vascular structure, and metabolic parameters are considerably disrupted in patients with type 1 diabetes. Omega-3 as an adjuvant therapy may exert profitable effects on type 1 diabetes and its complications by improving inflammation, oxidative stress, immune responses, and metabolic status. Because no randomized clinical trial has examined the effects of omega-3 consumption in children and adolescents with type 1 diabetes; the present study aims to close this gap. METHODS: This investigation is a randomized clinical trial, in which sixty adolescents with type 1 diabetes will be randomly assigned to receive either omega-3 (600 mg/day) or placebo capsules for 12 weeks. Evaluation of anthropometric parameters, flow-mediated dilation (FMD) as an endothelial function marker, carotid intima-media thickness (CIMT) as a vascular structure marker, proteinuria, biochemical factors including glycemic and lipid profile, blood urea nitrogen (BUN), creatinine, high-sensitivity C-reactive protein (hs-CRP), and erythrocyte sedimentation rate (ESR), as well as blood pressure will be done at the baseline and end of the trial. Also, dietary intake and physical activity will be assessed throughout the study. Statistical analysis will be performed using the SPSS software (Version 24), and P < 0.05 will be considered statistically meaningful. DISCUSSION: It is hypothesized that omega-3 supplementation may be beneficial for the management of type 1 diabetes and its complications by reducing inflammation and oxidative stress and also modulating immune responses and glucose and lipid metabolism through various mechanisms. The present study aims to investigate any effect of omega-3 on patients with type 1 diabetes. ETHICAL ASPECTS: This trial received approval from Medical Ethics Committee of Iran University of Medical Sciences, Tehran, Iran (IR.IUMS.REC.1400.070). TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20210419051010N1 . Registered on 29 April 2021.
BACKGROUND: Type 1 diabetes is a main health burden with several related comorbidities. It has been shown that endothelial function, vascular structure, and metabolic parameters are considerably disrupted in patients with type 1 diabetes. Omega-3 as an adjuvant therapy may exert profitable effects on type 1 diabetes and its complications by improving inflammation, oxidative stress, immune responses, and metabolic status. Because no randomized clinical trial has examined the effects of omega-3 consumption in children and adolescents with type 1 diabetes; the present study aims to close this gap. METHODS: This investigation is a randomized clinical trial, in which sixty adolescents with type 1 diabetes will be randomly assigned to receive either omega-3 (600 mg/day) or placebo capsules for 12 weeks. Evaluation of anthropometric parameters, flow-mediated dilation (FMD) as an endothelial function marker, carotid intima-media thickness (CIMT) as a vascular structure marker, proteinuria, biochemical factors including glycemic and lipid profile, blood urea nitrogen (BUN), creatinine, high-sensitivity C-reactive protein (hs-CRP), and erythrocyte sedimentation rate (ESR), as well as blood pressure will be done at the baseline and end of the trial. Also, dietary intake and physical activity will be assessed throughout the study. Statistical analysis will be performed using the SPSS software (Version 24), and P < 0.05 will be considered statistically meaningful. DISCUSSION: It is hypothesized that omega-3 supplementation may be beneficial for the management of type 1 diabetes and its complications by reducing inflammation and oxidative stress and also modulating immune responses and glucose and lipid metabolism through various mechanisms. The present study aims to investigate any effect of omega-3 on patients with type 1 diabetes. ETHICAL ASPECTS: This trial received approval from Medical Ethics Committee of Iran University of Medical Sciences, Tehran, Iran (IR.IUMS.REC.1400.070). TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20210419051010N1 . Registered on 29 April 2021.
Authors: Oindrila Raha; Subhankar Chowdhury; Samir Dasgupta; P Raychaudhuri; B N Sarkar; P Veer Raju; V R Rao Journal: Int J Diabetes Dev Ctries Date: 2009-04
Authors: Aleksandra Żebrowska; Katarzyna Mizia-Stec; Magda Mizia; Zbigniew Gąsior; Stanisław Poprzęcki Journal: Eur J Sport Sci Date: 2014-09-01 Impact factor: 4.050
Authors: Lauren L O'Mahoney; Gareth Dunseath; Rachel Churm; Mel Holmes; Christine Boesch; Antonios Stavropoulos-Kalinoglou; Ramzi A Ajjan; Karen M Birch; Nicolas M Orsi; Georgia Mappa; Oliver J Price; Matthew D Campbell Journal: Cardiovasc Diabetol Date: 2020-08-12 Impact factor: 9.951